← Russell 3000 cross-section

TSHA Taysha Gene Therapies, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-11, not restated
Healthcare

Scale

Market cap
$2.0bn
Revenue TTM
$6m
Net income TTM
$-150m
Free cash flow
$-133m
Composite score
38.9
Sector rank
#1656

Valuation

P / E
EV / EBITDA
EV / sales
282.7
FCF yield
-6.78%
Earnings yield vs 10-yr
-12.38pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-2,728.0%
EBITDA margin
-2,770.6%
ROE
-38.6%
ROIC
Revenue growth
-32.3%

Insider activity, last 90 days

Net open-market
$-1.25m
Buyers
0
Sellers
1

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

We are obligated to pay Abeona up to $26.5 million in regulatory-related milestones and up to $30.0 million in sales-related milestones per licensed product and high single-digit royalties on net sales of licensed products. Components of Results of Operations Revenue Revenue for the six months ended June 30, 2025 was derived from the Astellas Transactions. We recognized revenue as research and development activities related to our Rett program were performed. Revenue related to the material rights associated with the Rett Option and the GAN Option were recognized at a point in time when the option was exercised or the option period expired. …Taysha Gene Therapies, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →